Pfizer invests in Valneva, updates agreement on Lyme disease vaccine

Under a new deal, Pfizer buys 8.1% of the French firm’s shares, with proceeds going to an upcoming phase III trial of the word’s only Lyme disease vaccine candidate in development.

Photo: Mark Lennihan/AP/Ritzau Scanpix

Back in 2020, Valneva and US-based Pfizer partnered up on the development of the French firm’s vaccine candidate, VLA15, for Lyme disease, also known as Lyme borreliosis.

The two firms have now updated the existing agreement, and Pfizer further strengthens ties between them by investing around EUR 90.5m in Valneva, representing 8.1% of the firm’s share capital, according to a joint press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs